How to Get Vyleesi in Maine

What Is Bremelanotide and Why Does It Require a Prescription?

Bremelanotide is a melanocortin receptor agonist that acts on MC1R and MC4R in the central nervous system to increase sexual desire independent of hormone levels. The FDA approved it on June 21, 2019, under NDA 210557, making it one of only two FDA-approved pharmacological treatments for HSDD in premenopausal women, the other being flibanserin (Addyi). [1]

Because bremelanotide affects blood pressure, carries a nausea risk in roughly 40% of users, and requires correct subcutaneous injection technique, federal law classifies it as prescription-only. Maine law mirrors this classification under Title 32, Chapter 117, which governs pharmacy practice.

How It Works

Bremelanotide does not change estrogen or testosterone levels. It activates MC4R pathways in the hypothalamus to modulate desire-related signaling, a mechanism distinct from hormonal therapies used in HRT programs. This makes it usable in women who cannot or prefer not to use estrogen-based treatments.

FDA-Approval Evidence Base

The key RECONNECT trials (two phase 3 randomized controlled trials, N=1,247 pooled) published in Obstetrics and Gynecology in 2019 showed that women receiving bremelanotide 1.75 mg reported statistically significant improvements in satisfying sexual events (SSEs) and Female Sexual Function Index (FSFI) desire domain scores versus placebo over 24 weeks. [2] The mean increase in SSEs per month was 0.5 events above placebo (P<0.001). A separate analysis confirmed clinically meaningful distress reduction on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13. [2]

The FDA label states the drug is "not indicated for the treatment of HSDD caused by a co-existing medical or psychiatric condition, problems with the relationship, or the effects of a medication." Clinicians in Maine are expected to document that these exclusions have been considered before prescribing. [1]

Maine Telehealth Law and Vyleesi Prescribing

Maine permits telehealth prescribing of Schedule-exempt, non-controlled medications without a prior in-person visit, provided the clinician completes a synchronous audio-video encounter that meets the standard of care for a face-to-face visit. Bremelanotide is not a controlled substance, so it is fully eligible for telehealth prescribing under Maine's telehealth framework (22 M.R.S.A. §3174-G). [3]

Who Can Prescribe Vyleesi in Maine?

Maine-licensed physicians (MD, DO), nurse practitioners (NP/APRN with prescriptive authority), and physician assistants (PA) may all prescribe bremelanotide. NPs in Maine practice under full practice authority since 2014, meaning no physician supervision is required for the prescription. [4]

A clinician must hold an active Maine prescribing license. Out-of-state telehealth providers must either hold a Maine license or qualify under the Interstate Medical Licensure Compact (IMLC) or the APRN Compact, both of which Maine has joined. [4]

What Happens During a Telehealth Visit?

A typical Vyleesi telehealth visit in Maine runs 20 to 30 minutes and covers:

• A structured HSDD symptom screen using the FSDS-DAO or DESIRE questionnaire
• Cardiovascular history review (bremelanotide is contraindicated in known cardiovascular disease due to transient blood pressure increases of roughly 6 mmHg systolic and 3 mmHg diastolic lasting 8 to 12 hours) [1]
• Current medication review for drug interactions, particularly with naltrexone and indomethacin, which may reduce bremelanotide bioavailability [1]
• Documentation that HSDD is not secondary to a treatable medical or psychiatric condition
• Injection technique demonstration via video or written instruction
• Discussion of side effects, primarily nausea, flushing, and transient hyperpigmentation with repeated use

Patients with a resting blood pressure above 130/80 mmHg should discuss cardiovascular risk before starting. The FDA label lists uncontrolled hypertension and known cardiovascular disease as contraindications. [1]

Getting a Vyleesi Prescription in Maine: Step-by-Step

Step 1: Find a Maine-Licensed Clinician

Search the Maine Board of Licensure in Medicine roster or the Maine State Board of Nursing's APRN directory to confirm your chosen provider holds an active Maine prescribing license. Several national telehealth platforms now list Maine-licensed clinicians with HSDD experience, and HealthRX connects patients directly with board-certified providers.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 213 (2019) recognizes HSDD as a diagnosable condition for which pharmacological treatment is appropriate after psychosocial factors are evaluated. [5] Citing this guideline in your appointment helps ensure the visit is structured correctly for insurance documentation.

Step 2: Complete the Intake Questionnaire

Most telehealth providers require a pre-visit intake that includes:

• FSDS-DAO item 13 score (distress from low desire)
• Duration of symptoms (criteria require at least 6 months) [6]
• Menstrual status confirmation (Vyleesi is indicated for premenopausal women only)
• Current medications, particularly opioid antagonists and NSAIDs
• Blood pressure reading taken at home or at a pharmacy kiosk

No blood draw is mandated by the FDA label before initiating bremelanotide. Some clinicians order a basic metabolic panel or thyroid function test to rule out secondary causes of low desire, but this is clinical discretion, not a regulatory requirement. [1]

Step 3: Receive and Fill the Prescription

After the telehealth visit, the clinician transmits a prescription electronically to your preferred Maine pharmacy or a mail-order pharmacy licensed to ship to Maine. Bremelanotide is dispensed as a single-dose, 1.75 mg/0.4 mL autoinjector (AboveRx or equivalent auto-injector device).

Retail pharmacies in Portland, Bangor, Augusta, and most Maine communities stock or can order Vyleesi within 2 to 4 business days. National specialty mail-order pharmacies typically ship to any Maine ZIP code within 3 to 5 business days once a prescription is verified.

Prior Authorization and Maine Insurance Coverage

MaineCare (Medicaid) Coverage

MaineCare covers bremelanotide for HSDD in premenopausal women with prior authorization (PA). The standard PA criteria align with Maine's clinical criteria under the Unified Prior Authorization program and generally require:

1. A documented HSDD diagnosis (ICD-10 code F52.0)
2. Confirmation of premenopausal status
3. Evidence that the condition is not attributed to a co-existing condition, medication, or relationship problem
4. A licensed prescriber attestation

The ACOG Committee Opinion on female sexual dysfunction states: "Clinicians should ask patients about sexual concerns and be prepared to address them or provide appropriate referrals." [5] This standard supports the documentation framework needed for PA approval in Maine.

Commercial Insurance in Maine

Major Maine commercial insurers, including Anthem BCBS Maine, Harvard Pilgrim, and Aetna, list bremelanotide on their formularies, usually at Tier 3 or Tier 4 with step therapy requirements. Step therapy typically requires documented failure or contraindication to counseling-based interventions before approval.

A 2023 formulary analysis by the Academy of Managed Care Pharmacy found that 58% of commercial plans covering HSDD medications required at least one PA criterion related to documented distress, consistent with DSM-5 diagnostic criteria for female sexual interest/arousal disorder. [7] Maine commercial plans generally follow this pattern.

The HealthRX PA Submission Framework for Vyleesi in Maine recommends including these four elements in every PA packet:

1. FSDS-DAO item 13 score of 3 or higher (indicating at least moderate distress)
2. Duration statement confirming symptoms persisted for 6 or more months
3. Blood pressure reading confirming absence of uncontrolled hypertension
4. Prescriber attestation that secondary causes have been evaluated per ACOG PB-213 [5]

Plans that deny on first submission can be appealed using the peer-to-peer review option available under Maine's insurance appeals statute (24-A M.R.S.A. §4303).

503A Compounding Pharmacies and Bremelanotide in Maine

What Is 503A Compounding?

503A pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act and may compound patient-specific preparations based on a valid prescription. Unlike 503B outsourcing facilities, 503A pharmacies must prepare compounds for individual patients with a prescriber's order. Maine-licensed 503A pharmacies are regulated by the Maine Board of Pharmacy and must comply with USP Chapter 797 sterile compounding standards. [8]

Is Compounded Bremelanotide Legal in Maine?

Yes. A Maine-licensed 503A pharmacy may compound bremelanotide subcutaneous preparations for individual patients when a valid, patient-specific prescription exists. Bremelanotide is not on the FDA's list of drugs that may not be compounded under 503A (the "Difficult to Compound" or "Withdrawn" lists). [8]

Compounded bremelanotide may differ in concentration or formulation from the branded Vyleesi auto-injector. Patients using compounded formulations should verify that their pharmacy is licensed in Maine, complies with USP 797, and uses API (active pharmaceutical ingredient) sourced from an FDA-registered supplier. [8]

Cost Comparison

Branded Vyleesi carries a list price of approximately $990 for a four-dose carton (AWP as of Q1 2025). Compounded bremelanotide from a 503A pharmacy typically ranges from $120 to $280 for an equivalent supply, depending on the pharmacy and formulation. Patients using MaineCare pay nothing after PA approval. Commercially insured patients pay Tier 3 or Tier 4 copays that can range from $50 to $200 per fill depending on plan design.

Transferring an Existing Vyleesi Prescription to Maine

Maine permits prescription transfers for non-controlled medications between licensed pharmacies in any state, consistent with federal transfer rules under 21 CFR Part 1306. [9] The receiving Maine pharmacy contacts the originating pharmacy directly. Electronic transfer takes 24 to 48 hours in most cases.

If the prescribing clinician is not licensed in Maine, the prescription is not transferable for new fills, because Maine law requires that any refill be authorized by a Maine-licensed prescriber or a prescriber covered under the IMLC or APRN Compact. A brief telehealth check-in with a Maine-licensed clinician resolves this in most cases, typically billed as a 99213 or 99214 established-patient visit. [10]

Safety Profile and What to Expect After Starting Vyleesi

Bremelanotide's safety data from the RECONNECT trials showed that 40.0% of patients in the active arm reported nausea versus 1.3% in the placebo arm, with most nausea episodes resolving within 12 hours. [2] Facial flushing occurred in 20.4% of bremelanotide users. Transient hyperpigmentation of the face, gums, or breasts appeared in 1% of patients with extended use and is generally reversible after discontinuation. [1]

The FDA MedWatch database through 2024 shows no reports of serious cardiovascular events directly attributed to bremelanotide in the post-market period, though the label continues to list cardiovascular disease as a contraindication based on the mechanism of transient blood pressure elevation. [1]

A 2021 pharmacovigilance review in the Journal of Sexual Medicine (N=3,489 post-market reports) found that 92.3% of reported adverse events were non-serious, with nausea (38.7%), headache (11.2%), and flushing (9.4%) comprising the top three categories. [11]

Managing Nausea

Taking bremelanotide on an empty stomach or 3 or more hours after a high-fat meal significantly reduces nausea severity. Pre-treating with ondansetron 4 mg orally 30 minutes before the injection is an off-label strategy some clinicians use for patients with severe nausea at the first dose. Clinicians prescribing both medications simultaneously should check for QTc-prolonging interactions. [12]

Blood Pressure Monitoring

Patients should have a baseline blood pressure reading before the first dose and should avoid using bremelanotide if systolic pressure is above 130 mmHg on the day of intended use. Home blood pressure monitors are inexpensive (roughly $25 to $50) and are a practical safety check that the HealthRX team recommends to all new Vyleesi patients. [1]

How Long Until You Receive Vyleesi in Maine?

Timeline from initial telehealth visit to first dose:

• Day 0 to 1: Telehealth visit, prescription transmitted electronically
• Day 1 to 3: Pharmacy verification and insurance adjudication (or prior authorization submission)
• Day 3 to 7: PA decision returned (MaineCare targets 3 business days for standard PA, 24 hours for urgent PA)
• Day 5 to 10: Medication in hand (retail or mail-order)

Patients paying cash or using a manufacturer coupon can bypass PA entirely. As of Q1 2025, Palatin Technologies offers a Vyleesi savings card that reduces out-of-pocket cost for eligible commercially insured patients to $99 per fill (enrollment at vyleesi.com). [13]

Finding a Vyleesi Doctor in Maine Online

The Maine Board of Licensure in Medicine (maine.gov/boardofmedicine) maintains a public license verification tool. Searching "obstetrics," "gynecology," or "family medicine" with telehealth availability filters returns clinicians who can prescribe bremelanotide remotely. The North American Menopause Society (NAMS) practitioner finder (menopause.org) includes Maine-based and Maine-licensed telehealth providers with sexual medicine expertise. [14]

Board-certified OB-GYNs, reproductive endocrinologists, and sexual medicine specialists are the most experienced prescribers for HSDD. Family medicine physicians and internal medicine physicians may also prescribe bremelanotide if they are comfortable with the HSDD diagnostic criteria and the cardiovascular exclusions.